Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients

Figure 2

Patients’ metastasis-free survival prognosis according to MACC1 mRNA expression, KRAS mutation, BRAF mutation and MSI status. The Kaplan–Meier method was used to estimate cumulative survival rates. MFS time was defined as the time period from the date of surgery to the date of confirmed distant metastases or to the date of last follow-up contact/death for censored patients. A Patients with high MACC1 expression exhibited a statistically significant reduced MFS (P < 0.001). B No significant differences of MFS between KRAS mutated (G12 or G13) and KRAS wt tumors (P = 0.499) were detected. C KRAS G12 mutation showed no significant impact on MFS prognosis (P = 0.654). D MFS of patients with KRAS G13 mutated tumors compared to patients with KRAS wt was significantly reduced (P = 0.022). E There was no significant impact of BRAF V600 mutation on MFS prognosis (P = 0.656). F In MSS/MSI-L tumors we observed a tendency of shorter MFS (P = 0.085) compared to MSI-H tumors, but differences were not significant. G Tumors with high MACC1 expression and KRAS G13 exhibited the shortest MFS (mean: 19.0 months) compared to tumors with high MACC1 expression and KRAS wt (mean: 88.7 months, P = 0.039). Significance of differences in survival rates were assessed using the Log Rank test. P-values less than 0.05 were considered to be statistically significant.

Back to article page